Amgen delivered a strong Q2 2026 print on August 4, with total revenues up 10% year over year to $10.1 billion, GAAP diluted earnings per share up 65% to $4.37, and free cash flow of $3.5 billion that nearly doubled from the prior-year quarter. Six growth-driver products grew 26% and now produce roughly 70% of product sales, evidence that the portfolio reshuffle since the 2023 Horizon Therapeutics acquisition is paying off as legacy blockbusters such as Prolia and XGEVA face biosimilar pressure. The single most important observation in the report is not the headline EPS beat but the cash conversion: Amgen generated more free cash in Q2 2026 than in the entire first half of 2025 combined, which we read as the strongest signal that the GAAP-versus-non-GAAP gap (a 1.92 per share gap this quarter, driven by acquisition-related amortization) is becoming a self-funding story rather than a debt-funded one.
The mechanism behind the re-rating that we believe is not yet fully reflected in the equity is the convergence of three forces. First, the rare-disease franchise acquired through Horizon is now annualizing at the rate implied by the deal model, with Tepezza, Krystexxa, and Uplizna together contributing $1.3 billion in the quarter. Second, the next-generation growth drivers (Repatha at $953 million, Evenity at $714 million, Tezspire at $486 million) all grew more than 35% on volume, which we interpret as durable share gains rather than pricing tailwinds. Third, and most important for the next twelve months, the MariTide obesity program is approaching its first pivotal Phase 3 readout with the MARITIME-1 and MARITIME-2 chronic weight management studies ongoing. MariTide is Amgen's single largest bet, and a successful readout would reframe Amgen from a defensive biosimilar-exposed biotech into a credible second entrant in the GLP-1 obesity market, with the patient-friendly monthly or every-eight-week dosing schedule that Eli Lilly's Zepbound and Novo Nordisk's Wegovy cannot match.
The single load-bearing risk is the TAVNEOS franchise, a drug Amgen acquired through the 2022 ChemoCentryx purchase with $2.4 billion of developed-product-technology rights still on the balance sheet. On April 27, 2026, the FDA's Center for Drug Evaluation and Research proposed withdrawing TAVNEOS approval following a March 2026 Drug Safety Communication about serious and sometimes fatal drug-induced liver injury. Amgen requested a hearing on June 1, 2026, and submitted supporting materials on July 23, 2026. If the FDA withdraws approval, Amgen faces a non-cash impairment charge that we estimate could reach the full $2.4 billion carrying value, plus the loss of roughly $150 million of quarterly product sales and the $200 million-plus of in-flight research spend supporting the label.
The next data point that falsifies the bull thesis is the MariTide MARITIME-1 Phase 3 topline readout, currently expected in the first half of 2027. A clean safety and efficacy profile combined with a clear weight-loss delta versus the placebo arm would re-rate the stock. A second data point is the European Society of Cardiology (ESC) Congress in late August 2026, where Repatha VESALIUS-CV follow-on data are expected to be presented, providing an incremental evidence base for the cardiovascular outcomes story that supports Repatha's continued share gains in the statin-intolerant population.